Akums Drugs and Pharmaceuticals Ltd

Akums Drugs & Pharmaceuticals Ltd share price advanced by 5.14% to Rs 696.5 after the company's net profit soared by 24.15% to Rs 100.98 crore, while revenue from operations slightly gained 0.76% to Rs 1166.63 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.15%. It has inched up 0.86% over last one week and rose by 12.01% in last one month while the market capitalization of Akums Drugs & Pharmaceuticals Ltd has improved by 5.67% and 25% in the same period respectively. Profit before tax (PBT) of Akums Drugs & Pharmaceuticals Ltd stood at Rs 139.24 crore in Q2 FY26, expanding by 45.57% year-on-year, and advancing by 14.87% quarter-on-quarter. EBITDA came in at Rs 144 crore, jumping 41.14% YoY and rallying 23.95% sequentially. Total expenses softened by 1.27% to Rs 1033.02 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 682.12 crore, going up by 16.22% YoY, while employee benefits expense was at Rs 201.43 crore, ticking higher by 1.21% YoY. For the TTM ended FY26, revenue from operations inched higher 5.85% to Rs 4359.02 crore, while net profit tanked by 25.42% to Rs 256.4 crore, compared to previous TTM. EBITDA surged by 41246% to Rs 393.29 crore, and PBT registered a growth of 10.67% to Rs 382.1 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1181.2 crore in FY26, as against Rs 465.2 crore in FY25. Akums Drugs & Pharmaceuticals Ltd rallied 41.71% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.

Akums Drugs and Pharmaceuticals Limited will hold a board meeting on Saturday, August 8, 2026, to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing.

Akums Drugs & Pharmaceuticals announced that all manufacturing operations at the affected sites of the Company and its Subsidiaries, situated in the state of Uttarakhand, have been successfully resumed at 100% operations capacity with effect from 18 May 2026. The partial disruption in production at Haridwar sites lasted for four days which resulted in delayed supply of approx. Rs 20 crore. 

Akums Drugs & Pharmaceuticals announced that certain manufacturing sites at Haridwar have been impacted due to labour unrest at SIDCUL industrial area in Haridwar on 14 May 2026. The unrest has resulted in temporarily disruption of operations and active measures are being taken to normalize the operations.

Akums Drugs & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the special dividend of Rs 2 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Akums Drugs & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the final dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Akums Drugs & Pharmaceuticals announced that the 22th Annual General Meeting(AGM) of the company will be held on 10 July 2026.

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Net profit of Akums Drugs & Pharmaceuticals rose 1.75% to Rs 66.32 crore in the quarter ended December 2025 as against Rs 65.18 crore during the previous quarter ended December 2024. Sales rose 14.76% to Rs 1159.59 crore in the quarter ended December 2025 as against Rs 1010.41 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1159.591010.41 15 OPM %12.6612.01 - PBDT157.45130.79 20 PBT117.8086.27 37 NP66.3265.18 2 Powered by Capital Market - Live

Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 February 2026.Powered by Capital Market - Live